We’re pioneering precision-based medicines to revolutionize the treatment of kidney diseases.
Proteinuria in FSGS
We’re excited to launch our Proteinuria in FSGS Fact Stack! This is designed to be a ‘bite-sized’ education campaign to help explain the role that proteinuria plays in Focal Segmental Glomerulosclerosis (FSGS) and its use as a clinically meaningful endpoint to assess investigational kidney disease therapeutics, like GFB-887, our lead precision medicine candidate. Click through each fact!
Chronic kidney disease (CKD) affects 780 million people globally–that’s one in every ten people. Progression to end-stage kidney disease is common, and severely impacts quality of life. Despite this, fewer than 1% of all research programs across the biopharmaceutical industry are focused on reducing the substantial burden of CKD.
Of all active pipeline programs in the biopharmaceutical industry are for kidney diseases
Our Precision Medicine Approach to Treat Kidney Disease, Starting with FSGS
We are applying precision medicine to discover, develop and commercialize disease-modifying kidney disease treatments. We believe our approach enables us to uncover subsets of patients based on genetic and environmental factors within heterogenous kidney diseases.
We have a robust pipeline of novel, clinical-stage, precision medicine product candidates, including or lead program, GFB-887 for TRPC5-mediated FSGS, and other kidney diseases. All of our programs target kidney diseases with significant unmet medical needs
Goldfinch Bio Announces Publication in Science Advances on the Validation of Human Derived Organoids as a Predictable and Translatable Preclinical Model in Kidney Disease for the Evaluation of Therapeutic Drug Candidates
We aspire to be the world’s leading precision medicine kidney company – dedicated to our mission, focused on pursuing world-class science and fully committed to improving the lives of people with FSGS and other kidney diseases.